Sensory Analysis of Pharmaceutical Products Using Electronic Tongue and Nose

Oct 10, 2017

Pharmaceutical companies must now count taste and smell as new priorities during formulation development, especially for paediatric and geriatric medicines. Commonly, pharmaceutical laboratories have recourse to trained sensory panels in order to assess the sensory features of formulations. Fatma Ayouni, Technical and Application Specialist at Alpha MOS, explains why the electronic tongue, a taste analyser, and the electronic nose, a smell analyser, are considered as alternative solutions that meet the formulation department’s needs for safety, rapidity and cost-effectiveness. ...

Read More

Reducing Drug Discovery Timelines When Using Mouse Models

Oct 10, 2017

With the drug discovery timeline exceptionally long and late-stage failure rates very high, there is tremendous pressure to reduce the discovery timeframe and bring effective therapies to market sooner. How investigators approach studies that use lab animal models can directly impact those goals. Kenneth Albrecht, Ph.D., Scientific Program Manager at Taconic Biosciences, looks into the creative approaches to rodent model generation and breeding, and how they can significantly reduce the associated timeline while ensuring the timely availability of the high-quality models upon which drug discovery depends. ...

Read More

Using Intelligent Design to Deliver Safe Preservative-free Multidose Eye-drops

Oct 10, 2017

A significant patient population requires the long-term use of eye-drops multiple times a day. Maintaining the sterility of eye-drops is important for patient health. Single-use doses are expensive and preservatives can cause allergies and irritation, but the intelligent design of multi-dose bottles provides a viable means of delivering safe, preservativefree eye-drops, say Lilia Petit Ben Saidane and Benjamin Quaglia of Nemera. ...

Read More

Redefining the Art of Patient and Stakeholder Engagement in Rare Disease Clinical Research

Oct 10, 2017

Because of the rarity, heterogeneity and complex patient management associated with rare conditions, creating a pharmaceutical development programme for the treatment of one of these diseases is challenging. With this feature, Leslie Wetherell, Executive Director of Project Management and Rare Disease Franchise Lead at Worldwide Clinical Trials, explores the importance of patient and stakeholder engagement in rare disease clinical research. ...

Read More

The Future of Clinical Trials

Oct 10, 2017

The International Council on Harmonisation has adapted its guidelines to include radical changes to the design, implementation and monitoring of clinical trials. The principles are in place; the goals are clear. Essentially, industry and ICH appear to be working collaboratively to improve the patient experience, the quality of the data, access to metadata and overall transparency of results. Doug Stewart, Director of Hosted Employment and The Training Academy, shows that collaboration, cooperation, transparency and the patient are providing the direction of travel for clinical researchers. ...

Read More